300 related articles for article (PubMed ID: 30712845)
1. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Yin S; Gambe RG; Sun J; Martinez AZ; Cartun ZJ; Regis FFD; Wan Y; Fan J; Brooks AN; Herman SEM; Ten Hacken E; Taylor-Weiner A; Rassenti LZ; Ghia EM; Kipps TJ; Obeng EA; Cibulskis CL; Neuberg D; Campagna DR; Fleming MD; Ebert BL; Wiestner A; Leshchiner I; DeCaprio JA; Getz G; Reed R; Carrasco RD; Wu CJ; Wang L
Cancer Cell; 2019 Feb; 35(2):283-296.e5. PubMed ID: 30712845
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
3. SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation.
Cusan M; Shen H; Zhang B; Liao A; Yang L; Jin M; Fernandez M; Iyer P; Wu Y; Hart K; Gutierrez C; Nik S; Pruett-Miller SM; Stark J; Obeng EA; Bowman TV; Wu CJ; Lin RJ; Wang L
J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37463047
[TBL] [Abstract][Full Text] [Related]
4. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
[TBL] [Abstract][Full Text] [Related]
6. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
7.
López-Oreja I; Gohr A; Playa-Albinyana H; Giró A; Arenas F; Higashi M; Tripathi R; López-Guerra M; Irimia M; Aymerich M; Valcárcel J; Bonnal S; Colomer D
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37562845
[TBL] [Abstract][Full Text] [Related]
8. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
9. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
[TBL] [Abstract][Full Text] [Related]
10. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Woyach JA
Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
[No Abstract] [Full Text] [Related]
12. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
14. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Cheng S; Guo A; Lu P; Ma J; Coleman M; Wang YL
Leukemia; 2015 Apr; 29(4):895-900. PubMed ID: 25189416
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
18. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
19. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
20. SF3B1 mutations in chronic lymphocytic leukemia.
Wan Y; Wu CJ
Blood; 2013 Jun; 121(23):4627-34. PubMed ID: 23568491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
